Research programme: LRRK2 inhibitors - Denali/Genentech
Latest Information Update: 30 Aug 2016
At a glance
- Originator Genentech
- Developer Denali Therapeutics Inc
- Class Antiparkinsonians; Small molecules
- Mechanism of Action LRRK2 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Parkinson's disease